title: Results of an olmesartan medoxomil-based treatment regimen in hypertensive patients.
abstract: The efficacy and safety of an olmesartan medoxomil (OM)-based treatment algorithm was tested in a double-blind, randomized, placebo-controlled titration study in 276 patients with stage 1 or 2 hypertension. After placebo run-in, patients were randomized to placebo (12 weeks) or OM 20 mg/d (weeks 1-3). OM was up-titrated to 40 mg/d (weeks 4-6), then OM/hydrochlorothiazide (HCTZ) 40/12.5 mg/d (weeks 7-9) and OM/HCTZ 40/25 mg/d (weeks 10-12) were started if blood pressure (BP) remained > or =120/80 mm Hg at each time interval. End points were change from baseline in mean systolic BP (primary) and mean diastolic BP (secondary). OM-based treatment was well tolerated and changed BP by -22.3/-12.1 mm Hg from baseline vs -0.1/+0.8 mm Hg for placebo (P<.0001). Cumulative goal BP (<140/90 mm Hg) was achieved in 74.1% and 30.7% of OM- compared with placebo-treated patients, respectively (P<.0001). BP normalized (<120/80 mm Hg) in 44.8% of OM- vs 1.4% of placebo-treated patients with stage 1 hypertension (P<.0001).
authors.affiliation: Division of Cardiovascular Diseases, University of Alabama at Birmingham School of Medicine, AL, USA. soparil@uab.edu
authors.forename: Suzanne
authors.initials: S
authors.lastname: Oparil
authors.forename: Steven G
authors.initials: SG
authors.lastname: Chrysant
authors.forename: Dean
authors.initials: D
authors.lastname: Kereiakes
authors.forename: Jianbo
authors.initials: J
authors.lastname: Xu
authors.forename: Kathleen J
authors.initials: KJ
authors.lastname: Chavanu
authors.forename: William
authors.initials: W
authors.lastname: Waverczak
authors.forename: Robert
authors.initials: R
authors.lastname: Dubiel
mesh_terms: D000704:Analysis of Variance; D047228:Angiotensin II Type 1 Receptor Blockers / Q000009:adverse effects / Q000627:therapeutic use*; D000959:Antihypertensive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001794:Blood Pressure / Q000187:drug effects; D004232:Diuretics / Q000627:therapeutic use; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D006852:Hydrochlorothiazide / Q000627:therapeutic use; D006973:Hypertension / Q000188:drug therapy* / Q000503:physiopathology; D007093:Imidazoles / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D000068557:Olmesartan Medoxomil; D013777:Tetrazoles / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D047228:Angiotensin II Type 1 Receptor Blockers; D000959:Antihypertensive Agents; D004232:Diuretics; D007093:Imidazoles; D013777:Tetrazoles; D006852:Hydrochlorothiazide; D000068557:Olmesartan Medoxomil